中药联合抗结核药在难治性肺结核治疗中的应用

Application of Traditional Chinese Medicine Combined With Anti-tuberculosis Drugs in the Treatment of Refractory Pulmonary Tuberculosis

目的分析中药联合抗结核药在难治性肺结核患者临床治疗中的应用价值。方法选择我院于2009年1月—2017年12月收治的难治性肺结核患者82例作为研究对象。以数字表为参考,将所有患者划分为对照组与观察组,每组各41例。对照组患者接受抗结核药物口服治疗;观察组患者以对照组患者的治疗方案为基础,接受中药汤剂治疗,比较两组患者的临床治疗效果。结果两组患者治疗前的肺功能指标比较,差异无统计学意义(P> 0.05);治疗后,观察组患者的用力肺活量(FVC)、第1秒用力呼气容积(FEV_1)以及最大呼气流量(PEF)优于对照组,组间数据比较,差异具有统计学意义(P <0.05);观察组患者的治疗有效率为92.68%,不良反应发生率为7.32%,与对照组患者比较,差异具有统计学意义(P <0.05)。结论在难治性肺结核患者临床治疗期间,对患者行中药汤剂+抗结核药物联合治疗方案,不仅可以在短时间内改善患者的肺功能,而且安全性较好,有利于患者预后良性发展。

Objective To analyze the value of traditional Chinese medicine combined with anti-tuberculosis drugs in the clinical treatment of patients with refractory pulmonary tuberculosis.Methods 82 patients with refractory pulmonary tuberculosis admitted to our hospital from January 2009 to December 2017 were selected as the study subjects.Referring to the digital table,all patients were divided into control group and observation group,41 cases in each group.Patients in the control group received oral antituberculosis drugs.The patients in the observation group were treated with traditional Chinese medicine decoction on the basis of the treatment plan of the patients in the control group.The clinical effects of the two groups were compared.Results There was no significant difference in pulmonary function between the two groups before treatment (P > 0.05).After treatment,the forced vital capacity (FVC),forced expiratory volume (FEV1) and maximum expiratory flow (PEF) of the patients in the observation group were better than those in the control group,and the difference was statistically significant (P<0.05).The effective rate of treatment in the observation group was 92.68%,and the incidence of adverse reactions was 7.32%.Compared with the control group,the difference was statistically significant (P<0.05).Conclusion During the clinical treatment of patients with refractory pulmonary tuberculosis, the combination of traditional Chinese medicine decoction and antituberculosis drugs can not only improve the pulmonary function of patients in a short time,but also have better safety,which is conducive to the benign development of patients' prognosis.